411 results on '"Boursier, Jerome"'
Search Results
152. Cancer du sein infiltrant chez les femmes de moins de 25 ans: À propos de 13 cas
153. Rupture de varice rectale chez un malade avec cirrhose décompensée : efficacité de la ligature endoscopique: À propos d’un cas et revue de la littérature
154. The extra-hepatic complications of the metabolic syndrome are linked to the liver lesions of NAFLD: 1528
155. A new and accurate blood test for the non invasive diagnosis of nonalcoholic steatohepatitis in NAFLD patients: 1517
156. The evolution of liver stiffness predicts 4-year survival of patients with chronic hepatitis C: 1013
157. Liver disease progression and clinical outcomes in hepatic outcomes and survival fatty liver registry (HOTSURFR) study
158. Two-dimensional real-time shear wave elastography and risk for de novo hepatocellular carcinoma in patients with advanced chronic liver disease
159. Obeticholic acid improves experimental non-invasive markers of non-alcoholic steatohepatitis and advanced fibrosis: a secondary analysis of the phase 3 regenerate study
160. Long-term safety profile of cenicriviroc in adults with non-alcoholic steatohepatitis: rollover study
161. Liver stiffness measurement by fibroscan predicts the occurrence of liver-related events and death in patients with NAFLD-related compensated advanced chronic liver disease
162. The dynamics of FIB4 after sustained viral response predicts the risk of liver-related complication in HCV cirrhosis (ANRS CO12 Cirvir)
163. MACK-3: an accurate blood test for the diagnosis of fibrotic NASH and a candidate biomarker to monitor disease progression
164. Reply to: “Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward”
165. The usual blood liver markers provide a performant fibrosis test thanks to artificial intelligence
166. Reliablility criteria will discriminate accuracy of blood liver fibrosis tests
167. Simple blood fibrosis tests reduce unnecessary referrals for specialized evaluations of liver fibrosis in NAFLD and ALD patients
168. Tu1673 LONG-TERM SAFETY PROFILE OF CENICRIVIROC IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS: ROLLOVER STUDY
169. 334 OBETICHOLIC ACID IMPROVES EXPERIMENTAL NON-INVASIVE MARKERS OF NON-ALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS; RESULTS OF A SECONDARY ANALYSIS FROM THE MONTH-18 INTERIM ANALYSIS OF THE REGENERATE STUDY
170. Non-invasive diagnosis of patients with ‘at-risk’ NAFLD : only fibrosis counts?
171. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
172. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
173. Noninvasive diagnosis of liver fibrosis in NAFLD: Tips tricks
174. 2D-Shear-Wave elastography predicts survival in advanced chronic liver disease
175. Ethanol Extract of Leaves of Cassia siamea Lam Protects against Diabetes-Induced Insulin Resistance, Hepatic, and Endothelial Dysfunctions in ob/ob Mice
176. Phenotyping of circulating extracellular vesicles (EVs) in obesity identifies large EVs as functional conveyors of Macrophage Migration Inhibitory Factor
177. Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and Enhanced Liver Fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres
178. 938 Positive Results From REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH
179. Ethanol Extract of Leaves ofCassia siamea LamProtects against Diabetes-Induced Insulin Resistance, Hepatic, and Endothelial Dysfunctions inob/obMice
180. THU-299-Increased risk of mortality with liver disease progression in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients: An analysis of French national hospital care
181. GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH
182. SAT-411-Clinical comparison and conversion of international normalized ratio and prothrombin index
183. PS-201-External validation in NAFLD cohorts of the FibroScan-based FAST score combining liver stiffness, controlled attenuation parameter and AST to identify patients with active NASH (NAS ≥ 4) and significant fibrosis (F ≥ 2)
184. SAT-133-2D-Shear-Wave elastography predicts survival in advanced chronic liver disease
185. SAT-279-Comparison of different and new types of non-invasive fibrosis tests in NAFLD
186. PS-059-Increased healthcare resource utilization and costs in nonalcoholic fatty liver disease/non-alcoholic steatohepatitis patients with liver disease progression: A multivariate analysis of french national hospital care
187. THU-340-Epidemiology of NAFLD and advanced fibrosis in the French general population: A population-based cohort study in 118, 664 subjects (NASH-CO study)
188. PS-200-The combination of HEPAmet fibrosis score and transient elastography shows a high diagnostic accuracy in predicting advanced fibrosis in NAFLD
189. Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and Enhanced Liver Fibrosis score in patients with non‐alcoholic fatty liver disease from tertiary care centres.
190. Fibrosis assessment using FibroMeter combined to first generation tests in hepatitis C
191. A multisociety Delphi consensus statement on new fatty liver disease nomenclature
192. Metastatic hepatocellular carcinoma: When surgery and successive palliative treatments lead to remission
193. Nonalcoholic Fatty Liver Disease and the Gut Microbiome
194. Correction: Mouse Models of Diet-Induced Nonalcoholic Steatohepatitis Reproduce the Heterogeneity of the Human Disease
195. Mouse Models of Diet-Induced Nonalcoholic Steatohepatitis Reproduce the Heterogeneity of the Human Disease
196. Implication of Gut Microbiota in Nonalcoholic Fatty Liver Disease
197. Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis
198. The NAFLD burden on mortality and morbidities in general population: A community‐based longitudinal study (NASH‐CO study).
199. Compression ganglionnaire cholédocienne sur maladie des griffes du chat
200. Hyperplasie nodulaire régénérative dans les suites d’une tuberculose hépatique
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.